Central Nervous System Market Research CNS), Intelligence and Forescasts

CNS		email this page print page
Title		Publication Date		Price
MarketWatch: CNS		August 2008		£110
CNS Generic Drugs: Prospects and Opportunities to 2012		April 2008		£995
Commercial Insight: CNS Market Overview Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors		April 2008		£8000
Pharmacological and Psychosocial Treatments in Schizophrenia		January 2008		£35.95
Pipeline Insight Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries		November 2007		£2995
The CNS Market Outlook To 2012		October 2007		£1495
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed		September 2007		£7600
Commercial Insight: Migraine Opportunities Will Exist In The Wake Of Generic Attack		September 2007		£7600
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market		September 2007		£600
Commercial Insight: Epilepsy Companies Committed To The Cause Will Reap The Benefits		September 2007		£7600
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007		June 2007		£1999
CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities		June 2007		£995
Pipeline Insight: Depression Novel drugs to grow third-line market		March 2007		£6000
Innovations in CNS Novel therapeutics and future R&D strategies		January 2007		£1495
Stakeholder Insight: Multiple Sclerosis Disease-modifying efficacy and side effects guide treatment choice		December 2006		£8000
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines		December 2006		£8000
Pipeline Insight: Migraine Innovation essential as weak late-stage pipeline fails to hold off the impact of triptan patent expiries		December 2006		£6000
CNS Drug Discoveries: Multiple Sclerosis		November 2006		£795
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder (ADHD)		November 2006		£795
Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share		November 2006		£6000
CNS Market Outlook to 2011, The		November 2006		£1495
The CNS Market Outlook to 2011		November 2006		£1495
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors		October 2006		£6000
Pipeline Insight: Bipolar Disorder New treatments for bipolar depression set to drive near-term growth		September 2006		£6495
Global Market for Sleep-Wake Disorders, 2005-2012, The Trends, Opportunities, and Insights in a High-Value CNS Therapy Area		December 2005		£1100
Neuroscience Perspective; The Opportunities for Market Entry & Expansion		October 2005		£2235
Pipeline Insight: ADHD Shire Driving Diversity in ADHD		June 2005		£6000
The CNS Market Outlook to 2010		May 2005		£1495
Neurodegenerative Drug Futures		February 2005		£995
Neurogenomics and Neurotherapeutic Strategies New Directions in Platforms, Targets, and Therapeutic Approaches		February 2005		£1950
Trazadone: Business Insight		July 2004		£50